Dendreon Sets Provenge Price at $93,000 – Only 2,000 Patients Will Get it in First Year

29 April 2010 Filed under Dendreon, Prostate Cancer, Provenge, Vaccines Posted by » Comments Off

Dendreon is pricing Provenge high and for the first year its availability will be low, according to a report today in Xconomy, a Seattle business website. Provenge, the first immunotherapy to win FDA approval for treatment of men with prostate cancer, will cost $93,000 per patient. Only 2,000 patients will be treated with Provenge in the first year.

Luke Timmerman writes:

The product, sipuleucel-T (Provenge) will cost $31,000 per infusion, and patients will get three infusions over a one-month period, chief operating officer Hans Bishop said today on a conference call with analysts. That price is far higher than the $62,000 average estimate that Wall Street analysts had been expecting.

Full story at Xconomy 04/29/10

Trackback URL

Comments are closed.